MedTrace Logo

GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures

NCT03462680 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2021-11-17

Study results available
· View outcomes & findings →

Summary

Inflammation plays a central role in Parkinson's disease. The use of anti-inflammatory drugs was found to reduce the risk of PD . Niacin may play an important role in reducing inflammation in PD. The investigators also found that individuals with PD have a chronic niacin deficiency .

The purposes of this study are to (1) examine the blood, urine and spinal fluid of persons with Parkinson's to look for evidence of inflammation and; (2) whether 6 months of vitamin B3 supplements may reduce the inflammation and/or improve symptoms.

Conditions

Interventions

DIETARY_SUPPLEMENT

niacin

Niacin or nicotinic acid 250 mg tablets

OTHER

placebo

placebo tablet

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Chandramohan Wakade, MBBS · Charlie Norwood VA Medical Center, Augusta, GA

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-28
Primary Completion
2020-04-23
Completion
2020-04-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03462680 on ClinicalTrials.gov